• / Free eNewsletters & Magazine
  • / My Account
Home>Novacyt Strengthens Primerdesign Business with New Senior Hire

Novacyt Strengthens Primerdesign Business with New Senior Hire

Novacyt Strengthens Primerdesign Business with New Senior Hire

10/03/2017

Novacyt Strengthens Primerdesign Business with New Senior Hire

Paul Eros joins as Commercial Director, completing investment in the Group’s senior leadership team

Regulatory News:

Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces the appointment of Paul Eros as Commercial Director of Primerdesign, effective from 1 November 2017.

Paul has over thirty years’ of experience within the field of molecular diagnostics, including strategic global marketing, sales and product management. He joins Novacyt from DiaSorin, where he was Vice President of Molecular Marketing for over five years. Paul started his career with Becton Dickinson, quickly progressing through the sales and marketing organisation in both the UK and France, before joining Roche Diagnostics in 1999, where he held a number of senior international commercial and operational roles.

Paul’s appointment completes Novacyt’s investment in its senior commercial leadership team, building on the earlier Group appointments of Ruth Powell and Phil Sefton. Ruth Powell was appointed as Managing Director of the NovaPrep® division and Phil Sefton as Managing Director of Lab21 Products division.

Momentum within the Primerdesign business continues to build, driven by the strength of the commercial pipeline and increasing breadth of the molecular product offering. In addition, Primerdesign has increased its focus on building its business-to-business (“B2B”) pipeline which is developing well. Management expect this new vertical to form a significant part of future revenues and its first three B2B design prototyping and development contracts have recently been secured for delivery in Q4 2017.

©2017 Morningstar Advisor. All right reserved.